179O A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer

Programmed cell death-1 (PD-1) inhibitors have shown efficacy in cervical cancer as monotherapy. QL1604 is a humanized monoclonal antibody against PD-1 and has shown antitumor activity in phase (Ph) I study. Here we report the safety and efficacy results from a Ph II study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients (pts) with recurrent or metastatic cervical cancer.